Drug Profile
Icaritin - Shenogen Pharma
Alternative Names: IC-162; SNG 162Latest Information Update: 30 Jun 2023
Price :
$50
*
At a glance
- Originator Shenogen Pharma
- Developer Chinese Academy of Medical Sciences; Shenogen Pharma
- Class Antineoplastics; Benzopyrans; Flavonoids; Phenyl ethers; Small molecules
- Mechanism of Action Estrogen receptor alpha modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Liver cancer
- Discontinued Breast cancer; Solid tumours
Most Recent Events
- 20 Jun 2023 Shenogen Pharma in collaboration with Zhejiang Cancer Hospital plans a phase II trial for Liver cancer(Combination therapy) (PO, Capsule) (NCT05903456)
- 25 May 2023 Chemical structure information added
- 02 Feb 2023 Beijing Shenogen Biomedical terminates a phase III trial for Hepatocellular carcinoma (Late-stage disease) (NCT03236649)